| CHRS | PRESS-RELEASE | neutral | 1/10 | Coherus Oncology, Inc. announced it will report its Q1 2026 results on May 11, 2026. | May 4, 2026 |
| PLSE | 8-K | mixed | 6/10 | Pulse Biosciences reported Q1 2026 results with a GAAP net loss of $18.6M (-$0.27 EPS) that beat consensus estimates by | May 4, 2026 |
| GYRE | 8-K, DEFA14A | bullish | 7/10 | Gyre Therapeutics closed its all-stock acquisition of Cullgen Inc. on May 4, 2026, in a transaction valued at approximat | May 4, 2026 |
| AURA | PRESS-RELEASE | bearish | 7/10 | Aura Biosciences priced a large underwritten public offering of ~43.4M shares/pre-funded warrants at $6.00, expecting gr | May 4, 2026 |
| GYRE | PRESS-RELEASE | bullish | 7/10 | Gyre Therapeutics closed its all-stock acquisition of Cullgen Inc. for approximately $300 million, gaining a commercial- | May 4, 2026 |
| ANIK | CLUSTER | mixed | 5/10 | Anika Therapeutics insiders (CEO and director) purchased $223K in open-market shares in the week following the Q1 2026 e | May 4, 2026 |
| ALVOW | 6-K | neutral | 2/10 | Alvotech filed a 6-K announcing that General Counsel Tanya Zharov is stepping down after six years, effective after a ha | May 4, 2026 |
| LQDA | PRESS-RELEASE | neutral | 1/10 | Liquidia Technologies, Inc. announced it will report its Q1 2026 results on May 11, 2026. | May 4, 2026 |
| FBIO | PRESS-RELEASE | neutral | 2/10 | Fortress Biotech announced CEO participation in a fireside chat at the H.C. Wainwright Royalty Conference. No financial | May 4, 2026 |
| BCAX | PRESS-RELEASE | neutral | 1/10 | Bicara Therapeutics Inc. announced it will report its Q1 2026 results on May 11, 2026. | May 4, 2026 |
| FBLG | PRESS-RELEASE | neutral | 4/10 | FibroBiologics announced the release of the first cGMP batch of its CYWC628 drug product for a Phase 1/2 clinical trial | May 4, 2026 |
| ASRT | 8-K | bullish | 8/10 | Assertio agreed to be acquired by Garda Therapeutics in an all-cash deal at $21.80/share, a 63.1% premium to the unaffec | May 4, 2026 |
| CADL | PRESS-RELEASE | neutral | 3/10 | Candel Therapeutics announced a conference call on May 15, 2026, to discuss extended follow-up data from the Phase 3 tri | May 4, 2026 |
| CLNN | 8-K | bullish | 8/10 | Clene Inc. announces FDA agreement that its CNM-Au8 data may support accelerated approval NDA for ALS, with submission p | May 4, 2026 |
| LENZ | PRESS-RELEASE | neutral | 1/10 | LENZ Therapeutics, Inc. announced it will report its Q1 2026 results on May 11, 2026. | May 4, 2026 |
| EVAX | PRESS-RELEASE | neutral | 1/10 | Evaxion announced it will report its Q1 2026 results on May 7, 2026. | May 4, 2026 |
| IMNN | 8-K | neutral | 2/10 | Imunon entered into change-in-control severance agreements with its CEO, CMO, and General Counsel, providing 2.5x (CEO) | May 4, 2026 |
| JAGX | 8-K | bearish | 8/10 | Jaguar Health received a Nasdaq delisting notice on May 1, 2026, due to insufficient publicly held shares (~401,226 vs. | May 4, 2026 |
| KYTX | 8-K | neutral | 2/10 | Kyverna Therapeutics appointed Nadia Dac as Chief Commercial Officer, effective May 4, 2026. She brings over 30 years of | May 4, 2026 |
| MIRM | 8-K | bullish | 6/10 | Mirum Pharmaceuticals announced positive Phase 2b results for volixibat in PSC, meeting the primary endpoint with high s | May 4, 2026 |
| RLYB | 8-K | mixed | 6/10 | Candid Therapeutics terminated its merger agreement with Rallybio to enter a deal with UCB S.A. Rallybio receives a $50M | May 4, 2026 |
| ADCT | 8-K | neutral | 4/10 | ADC Therapeutics reported Q1 2026 product revenue of $20.0M (+15% YoY), in line with consensus, but GAAP net loss per sh | May 4, 2026 |
| TWST | 8-K | bullish | 7/10 | Twist Bioscience reported fiscal Q2 2026 revenue of $110.7M, a 19% YoY increase and above the prior quarter's $103.7M, w | May 4, 2026 |
| AXSM | 8-K | mixed | 6/10 | Axsome reported Q1 2026 revenue of $191.2M (+57% YoY), slightly above the $190.7M consensus, but net loss widened to -$6 | May 4, 2026 |
| BCRX | 8-K | bullish | 7/10 | BioCryst entered a European licensing agreement for navenibart (HAE) with Neopharmed Gentili, receiving $70M upfront and | May 4, 2026 |
| ADMA | 8-K | bullish | 6/10 | ADMA Biologics received FDA approval for label expansion of ASCENIV to include pediatric immune compromised patients age | May 4, 2026 |
| NXTC | PRESS-RELEASE | neutral | 4/10 | NextCure announced initiation of dose optimization for its CDH6-directed ADC SIM0505 in platinum-resistant ovarian cance | May 4, 2026 |
| APLS | 8-K | neutral | 2/10 | Apellis Pharmaceuticals amended its Executive Separation Benefits and Retention Plan in connection with its pending merg | May 4, 2026 |
| CNSP | 8-K | bearish | 7/10 | CNS Pharmaceuticals entered into a securities purchase agreement for a private placement of common stock and pre-funded | May 4, 2026 |
| INDV | 8-K | neutral | 3/10 | Indivior entered into a $175 million accelerated share repurchase agreement with Barclays as part of its existing $400 m | May 4, 2026 |
